Featured news from NHIVNA
HIV-related news from NAM
Sofosbuvir/ledipasvir and AbbVie 3D regimen cure most people with HCV genotype 4
Liz Highleyman, 2014-11-13 10:40:00
Sofosbuvir/ledipasvir without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for people with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston, USA.
HCV genotype 4, the most common type in the Middle East and North Africa, has not been as extensively studied as HCV genotypes 1, 2 and 3. While it has traditionally been considered "hard-to-treat" – and is often combined with genotype 1 in clinical trials – the optimal treatment for genotype 4 is not yet known.
Source:1
